Education
About Us
Working with TipRanks
Follow Us
Sandesh Mahatme Insider Profile
4 Followers
Sandesh Mahatme, EVP, CFO & CBO at Sarepta Therapeutics, holds 32.27K shares in Sarepta Therapeutics (Ticker: SRPT), holds ― shares in Spyre Therapeutics (Ticker: SYRE), holds ― shares in Crispr Therapeutics AG (Ticker: CRSP).
Sandesh Mahatme has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Sandesh Mahatme holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Sandesh Mahatme
Sandesh Mahatme's Trading History
Sarepta Therapeutics
Jul 09, 2020
EVP, CFO & CBO
Uninformative Sell
2.26M
$601.87K
Spyre Therapeutics
―
Director
―
―
Crispr Therapeutics AG
―
Director
―
―
Vor Biopharma
Jul 10, 2025
CFO
Uninformative Buy
―
$387.81M
Flexion Therapeutics
Jun 12, 2020
―
Uninformative Buy
―
$41.04K
List of latest transactions for each holding click on a transaction to see Sandesh Mahatme's performance on stock
You May Also Like
Sandesh Mahatme insider profile FAQ
What is the percentage of profitable transactions made by Sandesh Mahatme?
The percentage of profitable transactions made by Sandesh Mahatme is ―.
What is the average return per transaction made by Sandesh Mahatme?
The average return per transaction made by Sandesh Mahatme is ―.
What stocks does Sandesh Mahatme hold?
Sandesh Mahatme holds: SRPT, SYRE, CRSP, VOR, ~FLXN stocks.
What was Sandesh Mahatme’s latest transaction?
Sandesh Mahatme latest transaction was an Uninformative Sell of $2.26M.
What was Sandesh Mahatme's most profitable transaction?
Sandesh Mahatme’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Sandesh Mahatme's role in Sarepta Therapeutics?
Sandesh Mahatme's role in Sarepta Therapeutics is EVP, CFO & CBO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.